# Monoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months

> **Newsylist Open Intelligence Dossier** · First detected: 2026-08-31 10:29 UTC · Category: Health · Sources: 6 · Current Velocity: 3.67

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| UA.NEWS | Novartis drug reduced inflammation markers in Phase II study | 2026-08-29 16:33 | [Source Link](https://news.google.com/rss/articles/CBMioAFBVV95cUxORlVCWlF5RE9mUlFvYzBDT3BmZDBLdzEzVUsxZnhJeWZOdHpOa0RqVmtGXzNkaXFnZEVUbmFNS1FzcFRWTE5kWTN2M1NZTXhjTUk3eG9ibjZrU2JpWURCRDhKLXNPdTJTMnZxei1wNGlWOWwyeGNHUmhEb255WG4zd0lTd09pcXF0Z0hSeHFxQ1JwMUlDQi00OW13bTNvSTZ2?oc=5) |
| Newswise | Monoclonal Antibody Targeting Interleukin-6 Achieves Sustained Reductions in Inflammation Biomarkers Through Six Months | 2026-08-29 16:33 | [Source Link](https://news.google.com/rss/articles/CBMi6AFBVV95cUxQV2w4eEpsTVpjbWdicXIzVElvM2stUlFtOURfckwwamh6M1JObkoxSm5qRVpfOEd5ZU9ncXltUnFCdWhSVHd4REUyVlBVaTh1NldITzB5UFBoRjZtVjR3b08zdFREekctcUMyRmJIblRXc0lDR291WHBqRXVXNmNBV3liSk1TUF9HQzJMSWh1WlVZWU1PMFo0OWJxQkUtci0yMkNxOXIwbWJVcVNidEh5NE5kVnRRTGhnX29HUjhrQ2Y2R3REeGVTTVk3eUpueDhCdXd5QTEtTXJxZ3lUdXF1ck9lWHVsZk5a0gHoAUFVX3lxTFBXbDh4SmxNWmNtZ2JxcjNUSW8zay1SUW05RF9yTDBqaHozUk5uSjFKbmpFWl84R3llT2dxeW1ScUJ1aFJUd3hERTJWUFVpOHU2V0hPMHlQUGhGNm1WNHdvTzN0VER6Ry1xQzJ) |
| HCPLive | Pacibekitug Sustains Inflammatory Biomarker Reduction in CKD in TRANQUILITY Trial | 2026-08-29 16:33 | [Source Link](https://news.google.com/rss/articles/CBMirwFBVV95cUxNSHlUUXFRRk13Y19odVQxcHBQNVRqNXZXd0RaMEJicXZfZ1ZDbnJuWXpnNE5xQmtaOGJDcXpDVWpXVmNudWk2UHpXMUFkdVhqQkp3a0tIOUJkWndpTHJIZkVMYUd2VjV0ZzZ5LWJaclduM3ZRb3pnUEZudlpKaTczdVNtdWIyNl80OHVGRzFvRWVqbDZGejFPTEJpejBlME55WHdEbFN2MHBIMEw4UU1J?oc=5) |
| Endpoints News | #ESC26: Novartis pushes ahead with its IL-6 inhibitor despite Novo’s failure | 2026-08-29 16:33 | [Source Link](https://news.google.com/rss/articles/CBMingFBVV95cUxQdFhrZnpORlZuaVp4TDc3VFM4dlNjaFZsZGNsUTUyNEFMNTBnMXFQcmZ0U3FxQWNfbnkyellsZ3laUEIyOHZUdXZfN0E5dTNwMkRQYnVGbmFkSl9OYkNEZTA3ZktiUlhMeTYwNXhVNmVtSUFJRUVyOE5ldGRyWGtqUGRwUnFObl9FbXZHNS0zdldhRFZyck5tMVB2SUVpZw?oc=5) |
| STAT | A Novartis drug cut inflammation. Can it improve heart outcomes? | 2026-08-29 16:33 | [Source Link](https://news.google.com/rss/articles/CBMioAFBVV95cUxPb3NVbmljaXR2SF9QVk80MnBjdVdnVW5yWnBZeFg4Tk5IZVVxVUd5QVlvNUJzMlB1MVA5TmlGTmMtSU5jVVpQMUxDZkpiUTR5dm1wd19wa0RxNmdObDRkNzRTNVk0VEp2akdENHhVQzM5OF94bTNjd2JXRDdLaVYtQjhQeHNhdUFpR0RwZm1KZzhjUC10T3FtNmlYZzg5bnYt?oc=5) |
| Medical Xpress | Monoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months | 2026-08-29 16:33 | [Source Link](https://news.google.com/rss/articles/CBMinAFBVV95cUxQQUYzQlA3VnBTcTBUWVdZNmwycGpxbUU2Q0dDVzJvQ0xpd2xHNUZNZEd1bEh0QnE2eTlwWTFOdGZJMnkxZ3VHYkl6S0M4TTlzd2d4ZFJpSWxPOWVNbWstM3huSG5Malp5YXg4U3JzZkhNbWltcm5BNTR2UmwyenlKQzFreWZoWkJTN3NWSmZVdUxScEpBLXRHUENmN0w?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-08-31/monoclonal-antibody-targeting-interleukin-6-achieves-sustained-reductions-in*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*